Overview

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

To evaluate the long-term safety of desvenlafaxine sustained release (DVS-233SR) during open-label treatment of outpatients with major depressive disorder (MDD).

Phase:

Phase 3

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Desvenlafaxine Succinate